Catalent, Inc.

CTLT Details

Catalent, Inc. (NYSE: CTLT) is a global provider of advanced delivery technology, development solutions for drugs, protein, nucleic acid, gene therapy biologics, and commercial health products. Manufacturing and commercial product supply, development services, and clinical supply services are its key revenue sources. The Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery divisions of CTLT's advanced delivery technology platforms aid in the treatment of patients. The US accounts for the bulk of the company’s sales, followed by Europe and the rest of the world.

Commercial Supply Agreement with Edenbridge Pharmaceuticals, LLC: On August 10, 2021, Catalent signed a commercial supply contract with Edenbridge for an innovative formulation of glycopyrrolate that uses its proprietary Zydis orally disintegrating tablet (ODT) delivery technology and is intended for the treatment of peptic ulcer patients. The Zydis glycopyrrolate formulation is pending US FDA approval, expected in December 2021.

Commitment to Reduce Carbon Footprint: CTLT declared on August 3, 2021, that as of July 1, 2021, 97% of its electricity comes from renewable sources such as wind, solar, hydroelectric, and biomass. In addition, it will purchase renewable energy certificates for all its sites in North America, South America, Europe, and most of its Asia-based plants.

Collaboration with DisperSol: On August 2, 2021, DisperSol Technologies, a clinical-stage pharmaceutical firm, and Catalent announced a strategic manufacturing partnership to expedite various DisperSol generic pharmaceuticals development. A commercial-scale KinetiSol technology manufacturing line will be installed at Catalent's manufacturing plant in Somerset, New Jersey, as part of the collaboration.

9MFY21 Results: The company reported a 30.89% rise in net revenues to USD 2.81 billion during 9MFY21 (ended March 31, 2021) compared to USD 2.15 billion during 9MFY20, due to an increase in revenue from the Biologics division. It witnessed a massive growth in net earnings to USD 402.6 million during 9MFY21 compared to USD 66.5 million during 9MFY20. As of March 31, 2021, its balance sheet stood with cash and cash equivalents (including marketable securities) of USD 1.06 billion, with a total debt of USD 3.22 billion.

Key Risks: The company conducts its business in various regions worldwide, including North America, South America, Europe, and the Asia-Pacific regions. As a result, global economic and regulatory changes, such as inflation, recession, and political changes in countries where the company has operations, could hurt its operations and cash flows.

Outlook: For FY21, CTLT expects its net revenue to be in the range of USD 3.88 to 3.98 billion and adjusted EBITDA to be around USD 975 to 1,015 million. CTLT also anticipates its net income for FY21 to be between USD 500 to 540 million.

Valuation Methodology: Price/Earnings Multiple Based Relative Valuation

(Analysis by Kalkine Group)

* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.

CTLT Daily Technical Chart (Source: REFINITIV)

Stock Recommendation: CTLT's share price surged 37.29% in the past twelve months and is currently trading close to the higher end of the 52-week range of USD 79.65 to USD 127.68. The stock is currently trading above its 50 and 200 DMA levels, and its RSI Index is 62.18. We have valued the stock using the Price/Earnings-based relative valuation methodology and arrived at a target price of USD 109.11. Considering the uptick in the stock price, we believe the current price adequately reflects the business fundamentals and recommend a "Sell" rating on the stock at the current price of USD 120.25, down 1.21% as of August 10, 2021, 1:46 PM ET.

* The reference data in this report has been partly sourced from REFINITIV.

*All forecasted figures and industry information have been taken from REFINITIV.  

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine do not hold interests in any of the securities or other financial products covered on the Kalkine website.